Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer - Biodexa Pharmaceuticals (NASDAQ:BDRX), Cogent Biosciences (NASDAQ:COGT)
Benzinga·2026-02-19 11:31Zinger Key Point:MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST)Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) , a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with an increasing focus on products to treat or prevent gastrointestinal cancers, has added a new phase 1-ready candidate to its portfolio, this time to target gastrointestinal stromal tumors, or GIST. MTX240's ...